PL3240785T3 - Inhibitory drobnocząsteczkowe dehydrogenazy mleczanowej i sposoby ich wykorzystania - Google Patents

Inhibitory drobnocząsteczkowe dehydrogenazy mleczanowej i sposoby ich wykorzystania

Info

Publication number
PL3240785T3
PL3240785T3 PL15839113T PL15839113T PL3240785T3 PL 3240785 T3 PL3240785 T3 PL 3240785T3 PL 15839113 T PL15839113 T PL 15839113T PL 15839113 T PL15839113 T PL 15839113T PL 3240785 T3 PL3240785 T3 PL 3240785T3
Authority
PL
Poland
Prior art keywords
methods
small molecule
lactate dehydrogenase
molecule inhibitors
inhibitors
Prior art date
Application number
PL15839113T
Other languages
English (en)
Inventor
David J. Maloney
Ajit Jadhav
Ganesha Rai Bantukallu
Kyle Ryan BRIMACOMBE
Bryan T. Mott
Shyh Ming YANG
Daniel Jason URBAN
Xin Hu
Anton Simeonov
Jennifer L. KOUZNETSOVA
Alex Gregory Waterson
Gary Allen SULIKOWSKI
Kwangho Kim
Plamen CHRISTOV
Somnath JANA
Victor M. Darley-Usmar
Leonard M. Neckers
William J. Moore
Chi V. Dang
Original Assignee
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Vanderbilt University
The Trustees Of The University Of Pennsylvania
The Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Vanderbilt University, The Trustees Of The University Of Pennsylvania, The Uab Research Foundation filed Critical The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Publication of PL3240785T3 publication Critical patent/PL3240785T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL15839113T 2014-12-29 2015-12-29 Inhibitory drobnocząsteczkowe dehydrogenazy mleczanowej i sposoby ich wykorzystania PL3240785T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462097226P 2014-12-29 2014-12-29
PCT/US2015/067895 WO2016109559A2 (en) 2014-12-29 2015-12-29 Small molecule inhibitors of lactate dehydrogenase and methods of use thereof
EP15839113.6A EP3240785B1 (en) 2014-12-29 2015-12-29 Small molecule inhibitors of lactate dehydrogenase and methods of use thereof

Publications (1)

Publication Number Publication Date
PL3240785T3 true PL3240785T3 (pl) 2021-12-06

Family

ID=55451544

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15839113T PL3240785T3 (pl) 2014-12-29 2015-12-29 Inhibitory drobnocząsteczkowe dehydrogenazy mleczanowej i sposoby ich wykorzystania

Country Status (12)

Country Link
US (5) US10351532B2 (pl)
EP (2) EP3954685B1 (pl)
JP (3) JP6903580B2 (pl)
CN (1) CN107624112B (pl)
AU (2) AU2015374118B2 (pl)
CA (2) CA3210002A1 (pl)
DK (1) DK3240785T3 (pl)
ES (2) ES3042832T3 (pl)
HU (1) HUE055662T2 (pl)
PL (1) PL3240785T3 (pl)
SI (1) SI3240785T1 (pl)
WO (1) WO2016109559A2 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3954685B1 (en) * 2014-12-29 2025-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Small molecule inhibitors of lactate dehydrogenase and methods of use thereof
MX384833B (es) * 2016-01-21 2025-03-14 Zibo Biopolar Changsheng Pharmaceutical Co Ltd Inhibidores de tirosina quinasa de bruton
US10954228B2 (en) * 2016-06-29 2021-03-23 The Trustees Of The University Of Pennsylvania 1 H-pyrazol-1-yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof
TW201837026A (zh) 2017-01-10 2018-10-16 德商拜耳廠股份有限公司 作為除害劑之雜環衍生物（二）
KR102717600B1 (ko) 2017-10-06 2024-10-15 포르마 세라퓨틱스 인크. 유비퀴틴 특이적 펩티다제 30의 억제
CN112513036B (zh) 2018-05-17 2024-05-24 福马治疗有限公司 用作泛素特异性肽酶30抑制剂的稠合双环化合物
WO2020030613A1 (en) 2018-08-07 2020-02-13 Kemijski Institut Small molecule-inhibitors of 6-phosphofructo-1-kinase for reducing lactate generation by cancer cells
EP3632908A1 (en) 2018-10-02 2020-04-08 Inventiva Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer
ES2945834T3 (es) 2018-10-05 2023-07-07 Forma Therapeutics Inc Pirrolinas fusionadas que actúan como inhibidores de la proteasa 30 específica de ubiquitina (USP30)
TWI820231B (zh) 2018-10-11 2023-11-01 德商拜耳廠股份有限公司 用於製備經取代咪唑衍生物之方法
EP3883928A4 (en) 2018-11-22 2022-06-29 Qilu Regor Therapeutics Inc. Glp-1r agonists and uses thereof
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US10954221B2 (en) 2019-04-12 2021-03-23 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
CN114450399A (zh) * 2019-05-02 2022-05-06 卢万天主教大学 用于治疗癌症的乳酸脱氢酶抑制剂多肽
US11725026B2 (en) * 2019-06-28 2023-08-15 The Research Foundation For The State University Of New York Compositions and methods for inhibiting lactate dehydrogenase a activity
US20220331360A1 (en) 2019-08-07 2022-10-20 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services T cells having enhanced anti-tumor activity
US20250205203A1 (en) * 2020-05-18 2025-06-26 Chinook Therapeutics Canada, Inc. Substituted pyrazolyl compounds and methods of use thereof
US11752138B2 (en) 2020-05-18 2023-09-12 Vanderbilt University Treating primary or idiopathic hyperoxaluria with small molecule inhibitors of lactate dehydrogenase
JP2023528274A (ja) * 2020-05-18 2023-07-04 チヌーク セラピューティクス カナダ， インコーポレイテッド 置換ピラゾリル化合物及びその使用方法
US20230321135A1 (en) * 2020-06-08 2023-10-12 Qatar Foundation For Education, Science And Community Development Targeting of lactate dehydrogenase c, methods of preparing same, and methods of using same in combination with anti-cancer treatments
US20230247994A1 (en) 2020-07-02 2023-08-10 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
EP4255904A2 (en) * 2020-12-03 2023-10-11 Domain Therapeutics Novel par-2 inhibitors
WO2024212024A1 (en) * 2023-04-09 2024-10-17 Meta Pharmaceuticals (Hk) Limited Novel substituted pyrrole compounds, compositions comprising the substituted pyrrole compound, and methods of use thereof
WO2025011479A1 (en) * 2023-07-13 2025-01-16 Meta Pharmaceuticals (Hk) Limited Pyrazole based inhibitors of LDH and their use in immune and inflammatory diseases
WO2025026738A1 (en) 2023-07-31 2025-02-06 Bayer Aktiengesellschaft 6-[5-(ethylsulfonyl)-1-methyl-1h-imidazol-4-yl]-7-methyl-3-(pentafluoroethyl)-7h-imidazo[4,5-c]pyridazine derivatives as pesticides
WO2025241049A1 (en) * 2024-05-20 2025-11-27 Meta Pharmaceuticals (Hk) Limited Inhibitors of lactate dehydrogenase, compositions comprising the inhibitor, and methods of use thereof
WO2025241048A1 (en) * 2024-05-20 2025-11-27 Meta Pharmaceuticals (Hk) Limited Inhibitors of lactate dehydrogenase, compositions comprising the inhibitor, and methods of use thereof
WO2025241047A1 (en) * 2024-05-20 2025-11-27 Meta Pharmaceuticals (Hk) Limited Inhibitors of lactate dehydrogenase, compositions comprising the inhibitor, and methods of use thereof
CN118772058A (zh) * 2024-06-14 2024-10-15 济南尚博医药股份有限公司 一种2-氯-4-(1h-吡唑-3-基)苯甲腈的合成方法及应用

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182289A (en) 1988-06-14 1993-01-26 Schering Corporation Heterobicyclic compounds having antiinflammatory activity
US5128352A (en) * 1989-01-10 1992-07-07 Pfizer Inc. Anti-inflammatory 1-heteroaryl-oxindole-3-carboxamides
US5602113A (en) 1991-02-07 1997-02-11 Boehringer Ingelheim Pharmaceuticals, Inc. Pyridobenzo- and pyridiothieno-diazepines useful for the treatment of HIV infection
MX9205392A (es) 1991-10-29 1993-04-01 Du Pont Triazolcarbozamidas herbicidas y procedimiento para su obtencion.
JPH0680569A (ja) 1992-09-03 1994-03-22 Asahi Chem Ind Co Ltd 血小板凝集阻害剤
US5342851A (en) 1992-10-07 1994-08-30 Mcneil-Ppc, Inc. Substituted thiazole derivatives useful as platelet aggregation inhibitors
DE4405207A1 (de) 1994-02-18 1995-08-24 Bayer Ag N-Pyrazolylaniline und N-Pyrazolylaminopyridine
US20020028936A1 (en) 1999-04-12 2002-03-07 Gerhard Sperl 1,3-disubstituted indolin-2-ones for neoplasia
US6136079A (en) 1999-04-30 2000-10-24 Eastman Kodak Company Dye for ink jet ink
JP2003505369A (ja) 1999-07-15 2003-02-12 エヌピーエス アレリックス コーポレーション 偏頭痛を治療するための複素環式化合物
US6407238B1 (en) 1999-10-29 2002-06-18 Boehringer Ingelheim Pharmaceuticals, Inc. Process of making substituted pyrazoles
US6436965B1 (en) 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
JP2002167531A (ja) 2000-11-29 2002-06-11 Fuji Photo Film Co Ltd インクジェット記録用インク組成物及び画像形成方法
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
WO2003002062A2 (en) 2001-06-29 2003-01-09 Tularik Inc. Bis-aryl thiazole derivatives
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
US7320995B2 (en) 2002-08-09 2008-01-22 Eli Lilly And Company Benzimidazoles and benzothiazoles as inhibitors of map kinase
WO2004016592A1 (en) 2002-08-14 2004-02-26 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
WO2004043913A2 (en) 2002-11-08 2004-05-27 Trimeris, Inc. Hetero-substituted benzimidazole compounds and antiviral uses thereof
CN101333192A (zh) 2003-04-03 2008-12-31 默克公司 作为钠通道阻滞剂的联芳基取代吡唑
GB0323845D0 (en) 2003-10-10 2003-11-12 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
EP1794196A2 (en) 2004-09-22 2007-06-13 Symyx Technologies, Inc. Heterocycle-amine ligands, compositions, complexes, and catalysts, and methods of making and using the same
EP1807417A2 (en) 2004-11-04 2007-07-18 Neurogen Corporation Pyrazolylmethyl heteroaryl derivatives
WO2006077366A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflammation
EP1841766A1 (en) 2005-01-19 2007-10-10 Biolipox AB Pyrrolopyridines useful in the treatment of inflammation
US20090042949A1 (en) 2005-01-19 2009-02-12 Benjamin Pelcman Indoles Useful in the Treatment of Inflammation
EP1841736A1 (en) 2005-01-19 2007-10-10 Biolipox AB Indoles useful in the treatment of inflammation
JP2008527027A (ja) 2005-01-19 2008-07-24 バイオリポックス エービー 炎症の治療に有用なインドール類
US20080132510A1 (en) 2005-01-21 2008-06-05 Bingsong Han Imidazolylmethyl and Pyrazolylmethyl Heteroaryl Derivatives
GB0507198D0 (en) 2005-04-08 2005-05-18 Sb Pharmco Inc Process for preparing bicyclic compounds
US7456292B2 (en) 2005-06-30 2008-11-25 Bexel Pharmaceuticals, Inc. Hydroxamic acid-containing amino acid derivatives
WO2007018508A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetycholine receptor antagonists
WO2007018514A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
EP1922068A4 (en) 2005-08-16 2010-08-11 Icagen Inc INHIBITORS OF VOLTAGE-CONTROLLED SODIUM CHANNELS
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
AU2006298563A1 (en) 2005-10-06 2007-04-12 Merck & Co., Inc. Use of fused pyrrole carboxylic acids for the treatment of neurodegenerative and psychiatric diseases as D-amino acid oxidase inhibitors
US20090105238A1 (en) 2005-10-17 2009-04-23 Isagro Ricerca S.R.L Compounds and Relative use for the Control of Phytopathogens
WO2007048732A1 (de) 2005-10-28 2007-05-03 Basf Aktiengesellschaft Verwendung von 5-amino-pyrazolen zur bekämpfung pflanzenpathogener schadpilze, neue 5-amino-pyrazole, verfahren zu ihrer herstellung und sie enthaltende mittel
EP1998766A2 (en) 2005-12-16 2008-12-10 Ironwood Pharmaceuticals, Inc. Useful indole compounds
ITMI20052459A1 (it) 2005-12-22 2007-06-23 Isagro Spa Sali quaternari e relativo uso per il controllo di fitopatogeni
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
GB0614068D0 (en) * 2006-07-14 2006-08-23 Glaxo Group Ltd Compounds
WO2008009924A2 (en) 2006-07-18 2008-01-24 Biolipox Ab Indoles useful in the treatment of inflammation
EP2053920B1 (en) 2007-01-26 2014-04-30 North Carolina State University Inhibition of bacterial biofilms with imidazole derivatives
WO2008121861A2 (en) 2007-03-28 2008-10-09 Xenon Pharmaceuticals Inc. Pyrazole and pyrrole compounds useful in treating iron disorders
AR068063A1 (es) 2007-08-27 2009-11-04 Basf Plant Science Gmbh Co mpuestos de pirazol para controlar plagas de invertebrados
WO2009076454A2 (en) 2007-12-12 2009-06-18 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2009108551A2 (en) 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
WO2009137291A2 (en) 2008-05-08 2009-11-12 Merck & Co., Inc. Spiroazaindoles
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
WO2010007943A1 (ja) * 2008-07-17 2010-01-21 旭化成ファーマ株式会社 含窒素複素環化合物
AU2009272034B2 (en) * 2008-07-17 2011-10-13 Asahi Kasei Pharma Corporation Nitrogenated bicyclic heterocyclic compound
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
AU2009295936B2 (en) 2008-09-24 2014-07-17 Basf Se Pyrazole compounds for controlling invertebrate pests
CA2744016C (en) 2008-11-20 2018-12-11 Cambria Pharmaceuticals, Inc. Treatment of amyotrophic lateral sclerosis
CN102281816B (zh) * 2008-11-20 2015-01-07 人体媒介公司 用于确定危重护理参数的方法和设备
CN101747276B (zh) 2008-11-28 2011-09-07 中国中化股份有限公司 具有含氮五元杂环的醚类化合物及其应用
EP2373641B1 (en) 2008-12-04 2012-12-19 F. Hoffmann-La Roche AG Pyridazinone derivatives
MX2011006332A (es) 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
ES2660892T3 (es) 2009-03-23 2018-03-26 Merck Sharp & Dohme Corp. Antagonistas del receptor P2X3 para el tratamiento del dolor
JP5756457B2 (ja) 2009-04-06 2015-07-29 アジオス ファーマシューティカルズ， インコーポレイテッド ピルビン酸キナーゼｍ２調節剤、治療組成物および関連する使用方法
WO2011057942A1 (en) 2009-11-12 2011-05-19 Basf Se Insecticidal methods using pyridine compounds
JP2013515032A (ja) 2009-12-21 2013-05-02 ノバルティス アーゲー 二置換ヘテロアリール縮合ピリジン類
WO2011091410A1 (en) 2010-01-25 2011-07-28 Glaxos Smithkline Llc Trpv4 antagonists
JP2013542255A (ja) 2010-11-10 2013-11-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ミネラルコルチコイド受容体アンタゴニストとしてのピリジル尿素
WO2012074022A1 (ja) 2010-12-01 2012-06-07 旭硝子株式会社 イリジウムカチオン錯体および発光組成物
WO2012085167A1 (en) 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
JP2014506915A (ja) 2011-03-04 2014-03-20 ノバルティス アーゲー キナーゼ阻害剤としての四置換シクロヘキシル化合物
WO2012151440A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
JP5985611B2 (ja) 2011-05-03 2016-09-06 シンタ ファーマシューティカルズ コーポレーション 炎症および免疫関連用途のための化合物
WO2012154880A1 (en) 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases
JP2013040240A (ja) 2011-08-11 2013-02-28 Fujifilm Corp アゾ化合物、アゾ顔料、顔料分散物、着色組成物、カラーフィルター用着色組成物、カラーフィルター、カラーフィルター用着色組成物の調製方法、インクジェット記録用インク、印刷インク、塗料、染料、及び、レジストインク
CN103889989B (zh) 2011-08-24 2016-01-20 橘生药品工业株式会社 稠合杂环衍生物及其制药用途
ITPI20110143A1 (it) * 2011-12-20 2013-06-21 Univ Pisa Agenti terapeutici in grado di ridurre la produzione cellulare di acido lattico e composizioni farmaceutiche che comprendono tali composti
PL2804861T3 (pl) 2012-01-20 2018-08-31 Genosco Podstawione związki pirymidyny i ich zastosowanie jako inhibitory SYK
KR102018409B1 (ko) 2012-07-30 2019-09-04 다이쇼 세이야꾸 가부시끼가이샤 부분적으로 포화된 질소 함유 복소환 화합물
WO2014062938A1 (en) 2012-10-19 2014-04-24 Bristol-Myers Squibb Company Rory modulators
EP2934516A4 (en) 2012-12-20 2016-07-20 Merck Sharp & Dohme 3 ESTER 4 SUBSTITUTED OREXINE RECEPTOR ANTAGONISTS
US9556145B2 (en) 2012-12-20 2017-01-31 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-ester orexin receptor antagonists
EP2934517A4 (en) 2012-12-20 2016-05-25 Merck Sharp & Dohme 2-PYRIDYLOXY-3-NITRIL-4-SUBSTITUTED OREXINE RECEPTOR ANTAGONISTS
FR3001219A1 (fr) 2013-01-22 2014-07-25 Centre Nat Rech Scient Inhibiteurs de kinases
AU2014228489B2 (en) 2013-03-15 2018-11-15 Zymeworks Bc Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
KR20150121107A (ko) 2013-03-29 2015-10-28 코니카 미놀타 가부시키가이샤 이성체 혼합 금속 착체 조성물, 유기 일렉트로루미네센스 소자, 조명 장치 및 표시 장치
WO2014173880A1 (en) 2013-04-22 2014-10-30 Syngenta Participations Ag Novel microbiocides
WO2014176475A2 (en) 2013-04-26 2014-10-30 The Regents Of The University Of Michigan Egfr inhibitors and uses thereof
US9169221B2 (en) 2013-04-29 2015-10-27 Comsats Institute Of Information Technology Dihydro 1,4-benzoxazines and method of synthesizing the same using sulfonium salts
EP3954685B1 (en) * 2014-12-29 2025-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Small molecule inhibitors of lactate dehydrogenase and methods of use thereof

Also Published As

Publication number Publication date
CA2978823A1 (en) 2016-07-07
US10351532B2 (en) 2019-07-16
JP2023153302A (ja) 2023-10-17
US11897845B2 (en) 2024-02-13
CN107624112B (zh) 2022-03-04
EP3240785A2 (en) 2017-11-08
EP3954685A1 (en) 2022-02-16
WO2016109559A3 (en) 2016-08-25
JP7337883B2 (ja) 2023-09-04
AU2020257163A1 (en) 2020-11-19
JP2018503631A (ja) 2018-02-08
AU2015374118A1 (en) 2017-07-20
WO2016109559A2 (en) 2016-07-07
US20210323928A1 (en) 2021-10-21
AU2020257163B2 (en) 2022-06-30
US20180273488A1 (en) 2018-09-27
US10961200B2 (en) 2021-03-30
EP3240785B1 (en) 2021-07-07
SI3240785T1 (sl) 2021-11-30
CA3210002A1 (en) 2016-07-07
EP3954685B1 (en) 2025-08-27
US20240368087A1 (en) 2024-11-07
CN107624112A (zh) 2018-01-23
US20220220078A1 (en) 2022-07-14
US11247971B2 (en) 2022-02-15
ES3042832T3 (en) 2025-11-24
JP7771139B2 (ja) 2025-11-17
US20200002285A1 (en) 2020-01-02
JP6903580B2 (ja) 2021-07-14
DK3240785T3 (da) 2021-09-27
US12365653B2 (en) 2025-07-22
JP2021152064A (ja) 2021-09-30
CA2978823C (en) 2023-10-10
ES2883938T3 (es) 2021-12-09
AU2015374118B2 (en) 2020-07-23
HUE055662T2 (hu) 2021-12-28

Similar Documents

Publication Publication Date Title
HUE055662T2 (hu) Laktát-dehidrogenáz kismolekulás inhibitorai és alkalmazási eljárásai
IL285154A (en) Therapeutic inhibitor of lactate dehydrogenase and their factors
IL250415B (en) Antibodies against pd-l and methods of using them
EP3160498A4 (en) Il-15-based molecules and methods of use thereof
ZA201605639B (en) Hppd variants and methods of use
IL259801A (en) ezh2 inhibitors and methods of using them
GB201418350D0 (en) Dispenser and methods of use thereof
HUE061672T2 (hu) Glikán-interakcióban lévõ vegyületek és felhasználási módszerek
HUE050761T2 (hu) Vegyületek és alkalmazási eljárások
ZA201606243B (en) Hppd variants and methods of use
EP3226955A4 (en) Self-anchoring catheters and methods of use
EP3177327A4 (en) Inhibitors of myh7b and uses thereof
EP3190886A4 (en) Compositions and methods of use thereof
SG10201709955PA (en) Methods of treatment and compositions with xanthine oxidase inhibitors
EP3137873A4 (en) Viscometer and methods of use thereof
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
EP3134108A4 (en) Agents and methods of treatment
ZA201606450B (en) Compounds and their methods of use
IL266344A (en) Inhibitors of mtor-deptor interactions and methods of use thereof
EP3207029A4 (en) Tryptamide compositions and methods of use
EP3142999A4 (en) Methods and compositions of dasotraline for treatment of adhd
GB201417248D0 (en) Compostion and methods of treatment
EP3236966A4 (en) Combination of raf inhibitors and taxanes
GB201403697D0 (en) Compounds and methods of use
HK40032055A (en) Il-15-based molecules and methods of use thereof